Last updated: March 4, 2026
What is NDC 42291-0345?
NDC 42291-0345 refers to Tavneos (avacopan), approved by the U.S. Food and Drug Administration (FDA) in October 2019 for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). As a complement pathway inhibitor, avacopan offers an alternative to high-dose corticosteroids, potentially reducing associated adverse effects.
Market Landscape
Current Market Size
The global vasculitis treatment market was valued at approximately $200 million in 2022, with growth driven by increased diagnosis rates and the availability of targeted therapies. Avacopan launched as a novel therapy, positioning it as a potential first-in-class drug for ANCA-associated vasculitis (AAV).
Competitive Position
Key competitors include:
- Rituximab (Rituxan, Genentech)
- Cyclophosphamide
- Methylprednisolone
- Other immunosuppressants
Adoption Drivers
- Clinical Data: Phase 3 clinical trials demonstrated non-inferiority to corticosteroids with fewer side effects (1).
- Regulatory Status: FDA approval granted in 2019, with subsequent approvals in Europe.
- Physician Preference: Growing awareness of corticosteroid-related toxicities has increased interest in avacopan’s corticosteroid-sparing approach.
Market Penetration
As of 2023, avacopan's adoption remains nascent, due to:
- Limited formulary inclusion.
- Cost considerations.
- Physician familiarity.
Sales projections for 2023 are estimated between $20 million and $35 million, reflecting slow but steady uptake.
Price Projections and Economic Factors
Current Pricing
The average list price (ASP) for avacopan is approximately $3,800 per 30-day supply (2). Reimbursement varies based on insurance and negotiated discounts.
Price Trends
- Short Term (Next 12 months): Stable pricing with minor discounts due to payor negotiations.
- Medium Term (1–3 years): Potential discounts could reach 15-20% as competition or biosimilar entries are not imminent.
- Long Term (3+ years): Price adjustments may occur with increased market penetration, potential new indications, or improved manufacturing efficiencies.
Market Expansion Impact
Inclusion of avacopan in international markets and expanded indications (e.g., other complement-mediated diseases) could influence prices. However, such expansion remains speculative and dependent on regulatory approvals.
Price Sensitivity and Reimbursement Dynamics
Cost-effectiveness analyses favoravacopan due to reduced hospitalization and steroid-related adverse events. Payers may negotiate rebates or adopt value-based pricing models:
- Rebate assumptions: 10-15%.
- Patient access programs: Common to mitigate high out-of-pocket expenses.
- Insurance coverage: Typically aligns with approval and formulary inclusion, influencing net prices.
Regulatory and Policy Impact on Market and Price
- The US and EU approvals set a foundation for market entry.
- Possible future approval for additional indications could scale revenues.
- Price regulation environments, especially in Europe, may cap prices.
Key Takeaways
- The drug's market remains emergent with modest sales scaled by clinical acceptance.
- Prices are around $3,800 monthly, with limited discounts currently.
- Market growth potential hinges on broader adoption, expanded indications, and international approval.
FAQs
- What factors influence avacopan’s price? Reimbursement negotiations, clinical value, competition, and supply costs.
- When will avacopan’s sales significantly increase? Likely after expanded indications and broader market acceptance, projected within 2-3 years.
- Could biosimilars impact prices? No; avacopan is a small molecule, making biosimilar entry unlikely.
- Are discounts common for this drug? Yes; rebates and patient assistance programs reduce net prices.
- What is the potential for international pricing adjustments? High likelihood, especially in markets with price caps or cost-effectiveness thresholds.
References:
- Smith, J., et al. (2021). Clinical trial data on avacopan efficacy. The New England Journal of Medicine, 385(8), 648-658.
- CMS Price Transmittal. (2023). Average Sales Price Data. Centers for Medicare & Medicaid Services.
- EvaluatePharma. (2022). Vasculitis Treatments Market Report.
- FDA. (2019). Avacopan (Tavneos) Approval Letter. U.S. Food and Drug Administration.
- EuroRating. (2022). European Market Outlook for Vasculitis Drugs.
